LAB RESOURCES

Please indicate and briefly whether your institution provides any of the following core lab services or facilities to African investigators (select all that apply):

- Animal lab and/or non-human primate research facility:
- BSL-3 lab space and equipment:
- Bacteriology:
- Clinical Chemistry:
- DNA sequencing:
- Flow cytometry:
- Genomics:
- Immunology/immunopathogenesis:
- Pathology:
- Pharmacology/analytical chemistry:
- Virology/molecular biology:
- Other: My colleagues in other units offer the above.

BIOSTATISTICAL/DATA MANAGEMENT SUPPORT

Please indicate whether your institution provides any of the following core services to African investigators (select all that apply):

- My colleagues in other units offer the above.

TECHNICAL ASSISTANCE, CONSULTATION, AND SUPPORT

Please indicate whether your institution provides any of the following specialized technical expertise or support to African investigators (select all that apply):

- Social and Behavioral Sciences/Prevention
TRAINING AND EDUCATION

Does your institution offer degree and/or non-degree training to African scholars?

- Yes

Please indicate whether your institution offers any of the following research training programs that may be of relevance or interest to African investigators (select all that apply):

- Social science training

COLLABORATIONS

Please list and briefly describe your current collaboration with any African institutions for either research or training purposes.

- Makerere University, Faculty of Social Sciences

Please list and briefly describe your institution’s collaborations and/or partnerships with entities outside of Africa (e.g., organizations and networks in the USA, Europe, etc. – including CFARS, NIH clinical trials networks, HPTN, HVTN, AMC, IeDEA, USAID, PEPFAR, etc.):

- Collaborate with the CWRU CFAR, member of Cross-CFAR networks on social and behavioral research and on Cross-CFAR network on HIV and women.

CLINICAL COHORTS

Do you have access to existing clinical cohorts in Africa or USA?

- Yes

Please describe each existing clinical cohort that you have access to, including specifics like “HIV-TB infected HAART naïve adults”, sample size, sample type, sex, age, and whether clinical samples are currently being collected and/or stored (specify which samples).

- HIV-infected persons through our collaborators.

Are you planning to establish any new clinical cohorts over the next 5 years?

- No